New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 14, 2014
08:18 EDTGSK, THRXTheravance, GSK announce positive results from combination therapy COPD study
GlaxoSmithKline (GSK) and Theravance (THRX) announced positive results from three phase III studies. Two studies comparing the efficacy and safety of the combination anticholinergic / long-acting beta2-adrenergic agonist, Anoro Ellipta with inhaled corticosteroid / long-acting beta2-adrenergic agonist combination, Advair Diskus and the third comparing the efficacy and safety of Anoro Ellipta with Seretide Diskus 'FSC 500/50' in patients with chronic obstructive pulmonary disease, or COPD, and no history of moderate to severe COPD exacerbations in the last year. In each of the studies UMEC/VI achieved a statistically significant improvement in lung function, measured as weighted mean forced expiratory volume in one second over 0-24 hours at the end of the 12 week study, compared to either dose of FSC.
News For THRX;GSK From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
December 18, 2014
09:21 EDTGSKOn The Fly: Pre-market Movers
Subscribe for More Information
07:15 EDTGSKAgenus reports GSK ZOE-50 Phase 3 study met primary endpoint
Subscribe for More Information
December 9, 2014
10:23 EDTGSKOn The Fly: Analyst Downgrade Summary
Subscribe for More Information
09:10 EDTGSKARIAD takeover rumors rekindled, Independent says
Subscribe for More Information
07:44 EDTGSKAmerican Association for Cancer Research to hold a symposium
Subscribe for More Information
05:37 EDTGSKGlaxoSmithKline downgraded to Underperform from Neutral at BofA/Merrill
BofA/Merrill downgraded GlaxoSmithKline to Underperform citing a lack of pipeline catalysts and its belief the European pharma sector is close to fair value.
December 8, 2014
13:32 EDTGSKEpizyme announces results for PRMT5 inhibitor
Subscribe for More Information
December 5, 2014
06:04 EDTGSKGSK won't pursue divestment of certain brands in established products portfolio
As announced at the company’s Q2 results in July, GSK started a process to consider the divestment of certain North American and European brands in its Established Products Portfolio.The company has evaluated all bids received and has concluded, consistent with its key criteria of maximizing shareholder value, not to pursue divestment of these products.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use